


L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 19965-15-2 REGISTRY
CN Platinum, bis(O-ethyl carbonodithioato-.kappa.S,.kappa.S')-, (SP-4-1)-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Carbonodithioic acid, O-ethyl ester, platinum complex
CN Platinum, bis(hydrogen dithiocarbonato)-, O,O-diethyl ester (8CI)
CN Platinum, bis(O-ethyl carbonodithioato-S,S')-, (SP-4-1)-
OTHER NAMES:
CN Bis(ethyl xanthato)platinum
CN Bis(O-ethyl dithiocarbonato)platinum
CN Thioplatin
DR 3444-55-1
MF C6 H10 O2 Pt S4
CI CCS
LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, DRUGUPDATES, GMELIN*, IFICDB,
IFIPAT, IFIUDB, SYNTLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



22 REFERENCES IN FILE CA (1962 TO DATE)
22 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=>

L3 ANSWER 35 OF 35 PHARMAML COPYRIGHT 2003 MARKETLETTER
TI Antisoma in-licenses anticancer agent
AN 1654124 PHARMAML
TI Antisoma in-licenses anticancer agent
SO Marketletter October 31, 2000
DT Newsletter
WC 81
TX Antisoma in the UK has licensed-in an anticancer agent, called **thioplatin**, which has been developed by the German Cancer Research Center. **Thioplatin** has been described as a tumor-targeting version of a platin; it is only switched on by the acidic conditions found in tumor tissue and therefore is associated with greatly reduced toxicity. Antisoma feels that, although **thioplatin**'s efficacy is similar to cisplatin, the reduced side effects may enable the drug to be administered in higher doses than. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	188.76	191.45

STN INTERNATIONAL LOGOFF AT 10:07:52 ON 25 MAR 2003

L3 ANSWER 34 OF 35 PHARMAML COPYRIGHT 2003 MARKETLETTER
TI Antisoma cuts losses as revenues improve
AN 1655477 PHARMAML
TI Antisoma cuts losses as revenues improve
SO Marketletter February 9, 2001
DT Newsletter
WC 188
TX Moreover, Antisoma notes that: a new preclinical anti-angiogenesis development program commenced using humanized MAb BC-1; and **Thioplatin**, a tumor-targeting version of a platinum-based drug that forms the gold-standard treatment for solid tumors (including lung, ovarian and testicular. . .

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
AN 2000421762 EMBASE
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).
ISSN: 0031-7136 CODEN: PZSED5
CY Germany
DT Journal; Note
FS 016 Cancer
037 Drug Literature Index
LA German
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
CT Medical Descriptors:
 *tumor cell: DT, drug therapy
 antineoplastic activity
 cytostasis
 cancer chemotherapy
 glucose metabolism
 human
 note
 *cisplatin derivative: DT, drug therapy
 ***thioplatin**: DT, drug therapy
 antineoplastic agent: DT, drug therapy
 unclassified drug

L3 ANSWER 28 OF 35 ADISINSIGHT COPYRIGHT 2003 (ADIS)
CN **Thioplatin**

TX TEXT
Introduction:
Thioplatin is a tumour-targeted version of a platin that is switched on only in the acidic conditions typically found in . . . doses of platinum to be used which in turn should create higher therapeutic efficacy and reduced toxicity. Antisoma has licensed **thioplatin** from the originators of the compound at the German Cancer Research Centre in Heidleberg, Germany, through an agreement negotiated between . . . independent technology transfer company created by the Cancer Research Campaign to provide services for commercialisation to cancer research institutions worldwide. **Thioplatin** is currently in preclinical development, with the agent showing good activity in controlling the growth of non-small cell lung cancer in animal models. Further work on the formulation is being conducted before **thioplatin** can enter clinical trials. This means that **thioplatin** will not start clinical studies in 2002 as originally anticipated.
The company has a cooperation and supply agreement with W.C. Heraeus GmbH & Co. KG of Germany to develop methods for producing the active ingredients for **thioplatin**.

Financial Figures

The Financial Time (ft.com) reported on March 5, 2001 that branded platinum products have annual sales. . . that it had plans to raise up to Lstg 12 million (\$US17.6 million) to fund development of compounds such as **thioplatin**, which was in-licensed in October 2000; Antisoma was also looking at extending its current product pipeline.

TX PHARMACOLOGY:
Pharmacodynamics (Cancer):
 Preclinical studies: preliminary results from in vitro studies have shown

that thioplatin was active in 3 human ovarian cancer cell lines
that had acquired resistance to cisplatin/1/.

L3 ANSWER 29 OF 35 DRUGU COPYRIGHT 2003 THOMSON DERWENT
AN 84055 DRUGU
FS Registry
DDRN DR0053595
DDN **THIOPLATIN**
CT CYTOSTATICS
SS COMPLEX; XANTHOGENATE; PLATINUM-COMPLEX
DDN **THIOPLATIN**

TI Antisoma licenses new anticancer
AN 2000:19551 PHIN
DN S00685590
DED 8 Nov 2000
TI Antisoma licenses new anticancer
SO Scrip (2000) No. 2590 p8
DT Newsletter
FS BRIEF
TX The UK biotechnology company, Antisoma, has licensed **Thioplatin**,
a new "platin" anticancer agent from the German Cancer Research Centre in
Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
AN 2000:20176 PHIN
DN S00686592
DED 7 Nov 2000
TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
SO Scrip-Online-plus (2000)
DT Newsletter
FS FULL
TX

Anticancer, alkylating (K1B)

Product Name Originator

Thioplatin Antisoma

Radio/chemosensitizer (K5A)

Product Name Originator

tesmilifene York Medical

Anticancer, other (K6Z)

Product Name Originator

Apollo technology Procter & Gamble

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
AN 2000421762 EMBASE
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).
 ISSN: 0031-7136 CODEN: PZSEDS
CY Germany
DT Journal; Note

TI COMPANY NEWS - Antisoma plc (UK)
AN 2001:733 PHIN
DN B00690682
DED 1 Dec 2000
TI COMPANY NEWS - Antisoma plc (UK)
SO Bioventure-View (2000) No. 1512 p27
DT Newsletter
FS BRIEF
TX Antisoma plc London, UK (Easdaq: ASOM / LSE: ASM) Antisoma has in-licensed **Thioplatin**, a tumour targeting version of platin, from the German Cancer Research Centre. Platin is a platinum-based drug class that forms. . .

L3 ANSWER 25 OF 35 PHIN COPYRIGHT 2003 PJB

TI Antisoma licenses new anticancer
AN 2000:19551 PHIN
DN S00685590
DED 8 Nov 2000
TI Antisoma licenses new anticancer
SO Scrip (2000) No. 2590 p8
DT Newsletter
FS BRIEF
TX The UK biotechnology company, Antisoma, has licensed **Thioplatin**, a new "platin" anticancer agent from the German Cancer Research Centre in Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
AN 2000:20176 PHIN
DN S00686592
DED 7 Nov 2000
TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
SO Scrip-Online-plus (2000)
DT Newsletter
FS FULL
TX

Anticancer, alkylating (K1B)

Product Name Originator

Thioplatin Antisoma

Radio/chemosensitizer (K5A)

Product Name Originator

tesmilifene York Medical

Anticancer, other (K6Z)

Product Name Originator

Apollo technology Procter & Gamble

L3 ANSWER 27 OF 35 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI [Specific attack of **thioplatin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

AN 2000421762 EMBASE

TI [Specific attack of **thioplatin** on tumor cells].

THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.

SO Pharmazeutische Zeitung, (16 Nov 2000) 145/46 (34).
ISSN: 0031-7136 CODEN: PZSEDS
CY Germany
DT Journal; Note
FS 016 Cancer
037 Drug Literature Index
LA German
TI [Specific attack of **thioplatin** on tumor cells].
 THIOPLATIN GREIFT TUMORZELLEN SPEZIFISCHER AN.
CT Medical Descriptors:
 *tumor cell: DT, drug therapy
 antineoplastic activity
 cytostasis
 cancer chemotherapy
 glucose metabolism
 human
 note
 *cisplatin derivative: DT, drug therapy
 *b*thioplatin*: DT, drug therapy
 antineoplastic agent: DT, drug therapy
 unclassified drug

L3 ANSWER 28 OF 35 ADISINSIGHT COPYRIGHT 2003 (ADIS)
CN **Thioplatin**

TX TEXT
Introduction:
 Thioplatin is a tumour targeted version of a platin that is switched on only in the acidic conditions typically found in. . . doses of platinum to be used which in turn should create higher therapeutic efficacy and reduced toxicity. Antisoma has licensed **thioplatin** from the originators of the compound at the German Cancer Research Centre in Heidleberg, Germany, through an agreement negotiated between. . . independent technology transfer company created by the Cancer Research Campaign to provide services for commercialisation to cancer research

TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
AN 2000:309550 NLDB
TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
SO Cancer Weekly, (14 Nov 2000) .
PB Charles W. Henderson
DT Newsletter
LA English
WC 221
TI **Thioplatin** Platinum-Based, Targeted Anti-Cancer Therapy
In-Licensed.
TX **Thioplatin** is a tumor-targeting version of a platin, the "gold standard," platinum-based drug class that forms the cornerstone of cancer treatments. . .

Thioplatin, which was developed by Dr. Eberhard Amtmann at DKFZ in Heidelberg in collaboration with a chemist at the University of Heidelberg, is only "switched on" by the acidic conditions typically found in tumors, leaving healthy tissues essentially undamaged. Experiments using **Thioplatin** in isolated tumor cells and in animal models have shown that, while its efficacy is similar to that of the widely-used platinum-based drug cisplatin, its toxicity is strongly reduced. This indicates that it may be possible to give **Thioplatin** in higher doses than conventional platinum-based drugs, thereby potentially increasing the cancer-killing effect. The drug is expected to enter clinical. . .

L3 ANSWER 24 OF 35 PHIN COPYRIGHT 2003 PJB

TI COMPANY NEWS - Antisoma plc (UK)
AN 2001:733 PHIN
DN B00690682
DED 1 Dec 2000
TI COMPANY NEWS - Antisoma plc (UK)
SO Bioventure-View (2000) No. 1512 p27
DT Newsletter
FS BRIEF
TX Antisoma plc London, UK (Easdaq: ASOM / LSE: ASM) Antisoma has in-licensed **Thioplatin**, a tumour targeting version of platin, from the German Cancer Research Centre. Platin is a platinum-based drug class that forms. . .

L3 ANSWER 25 OF 35 PHIN COPYRIGHT 2003 PJB

TI Antisoma licenses new anticancer
AN 2000:19551 PHIN
DN S00685590
DED 8 Nov 2000
TI Antisoma licenses new anticancer
SO Scrip (2000) No. 2590 p8
DT Newsletter
FS BRIEF
TX The UK biotechnology company, Antisoma, has licensed **Thioplatin**, a new "platin" anticancer agent from the German Cancer Research Centre in Heidelberg. The terms of the deal were not. . .

L3 ANSWER 26 OF 35 PHIN COPYRIGHT 2003 PJB

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
AN 2000:20176 PHIN
DN S00686592
DED 7 Nov 2000

TI PHARMAPROJECTS - New Anticancer Products for week ending 03 November 2000
SO Scrip-Online-plus (2000)
DT Newsletter
FS FULL

TI Antisoma in-licenses anticancer agent.

AN 2000:296476 NLDB

TI Antisoma in-licenses anticancer agent.

SO Marketletter, (6 Nov 2000) .

ISSN: 0951-3175.

PB Marketletter Publications Ltd.

DT Newsletter

LA English

WC 81

TX Antisoma in the UK has licensed-in an anticancer agent, called **thioplatin**, which has been developed by the German Cancer Research Center. **Thioplatin** has been described as a tumor-targeting version of a platin; it is only switched on by the acidic conditions found in tumor tissue and therefore is associated with greatly reduced toxicity. Antisoma feels that, although **thioplatin**'s efficacy is similar to **cisplatin**, the reduced side effects may enable the drug to be administered in higher doses than. . .

TI OTHER NEWS TO NOTE.
AN 2000:292514 NLDB
TI OTHER NEWS TO NOTE.
SO BIOWORLD Today, (31 Oct 2000) Vol. 11, No. 211.
PB American Health Consultants, Inc.
DT Newsletter
LA English
WC 1326
TX Antisoma . . . anticancer agent from the German Cancer Research Center, of Heidelberg, Germany. No financial terms were disclosed in the deal for **thioplatin**, a tumor-targeting version of a platin, a platinum-based solid tumor therapeutic.

L3 ANSWER 6 OF 35 IFIPAT COPYRIGHT 2003 IFI DUPLICATE 1
TI MEDICAMENT CONTAINING PLATINUM COMPLEX COMPOUNDS AND THE USE THEREOF;
ANTICANCER AGENTS
AN 10061018 IFIPAT;IFIUDB;IFICDB
TI MEDICAMENT CONTAINING PLATINUM COMPLEX COMPOUNDS AND THE USE THEREOF;
ANTICANCER AGENTS
INF Amtmann; Eberhard, Heidelberg, DE
Schilling; Gerhard, Ladenburg, DE
IN Amtmann Eberhard (DE); Schilling Gerhard (DE)
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG PALMER & DODGE, LLP, ONE BEACON STREET, BOSTON, MA, 02108-3190, US
PI US 2002004526 A1 20020110
AI US 2001-784618 20010215
PRAI DE 1998-19838547 19980825
FI US 2002004526 20020110
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 11
GI 5 Figure(s).
FIG. 1 tumor regression and growth, respectively, after the treatment of a parvocellular bronchial carcinoma with a compound according to the invention and control, respectively,
FIG. 2 anti-tumoral effect of a compound according to the invention on a human colon carcinoma in naked mice,
FIG. 3 pH value-dependent effectiveness of cytostatic agents,
FIG. 4 anti-tumoral effect of **thioplatin** on human xenotransplants,
FIG. 5 histopathology of kidney and small intestine after treatment with **thioplatin** and cisplatin.
AB The present invention relates to a pharmaceutical preparation containing at least one compound of general formula (I)

D R A W I N G

wherein R1 and R2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents. This invention also relates to the use of the pharmaceutical preparations for the immunosuppressive treatment and for the non-invasive treatment.

GI . . .
invention on a human colon carcinoma in naked mice,
FIG. 3 pH value-dependent effectiveness of cytostatic agents,
FIG. 4 anti-tumoral effect of **thioplatin** on human xenotransplants,
FIG. 5 histopathology of kidney and small intestine after treatment with **thioplatin** and cisplatin.

L3 ANSWER 7 OF 35 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
TI **Thioplatin:** A sulfur-containing platinum complex possessing greater activity in acidic pH, non-cross resistance with cisplatin and antitumor activity in vivo.
AN 2002:367409 BIOSIS
DN PREV200200367409
TI **Thioplatin:** A sulfur-containing platinum complex possessing greater activity in acidic pH, non-cross resistance with cisplatin and antitumor activity in vivo.

AU Rowlinson-Busza, Gail (1); Griffiths-Johnson, David (1); Hadfield,